Abbott Profit Declines 19% As Charges Offset Higher Sales

Abbott Laboratories said on Wednesday its first-quarter earnings fell 19% as charges related to acquisitions and cost-cutting offset sharply higher sales of its prescription drugs and medical devices.

Shares fell , but results topped the average Wall Street forecast, making Abbott the fourth largest U.S. drugmaker this month to report earnings above analysts' estimates.

Excluding special items, Abbott earned 55 cents a share.

Analysts surveyed by Thomson Financial predicted a profit of 52 cents a share with sales of $5.26 billion.

Net earnings were $697.5 million, or 45 cents a share, down from $865 million, or 56 cents a share, in the year-earlier period.

Abbott's sales jumped almost 16% to $5.3 billion, a tad higher than Wall Street forecasts, helped by new products from acquisitions and favorable foreign exchange factors.

Prescription drug revenue rose almost 17% to $3.37 billion as its injectable Humira treatment for rheumatoid arthritis continued to grow by leaps and bounds, and drugs to raise "good" HDL cholesterol, acquired in a recent merger, continued to help results.

Sales of Humira, which targets the same inflammatory protein as Wyeth's Enbrel and Johnson & Johnson's Remicade, rose 46% to $571 million.

Abbott slightly raised its 2007 earnings forecast, to a range of $2.79 to $2.85 per share, citing higher-than-expected revenue in the first quarter from its TAP joint venture with Takeda Pharmaceutical Co.

Contact U.S. News


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video